Trial Profile
A clinical trial of OXS-C3550
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs GTB 3650 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors GT Biopharma
- 26 Mar 2024 According to a GT Biopharma media release, phase 1 trial with GTB-3650 anticipated to start in 2H 2024; and anticipate having initial data by the end of 2024/early 2025
- 04 Dec 2023 According to a GT Biopharma media release, the company announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for the development of GTB-3650 for the treatment of patients with CD33+ leukemia, including relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
- 01 Nov 2023 According to a GT Biopharma media release, Following FDA acceptance, the company plan to host a KOL event highlighting the anticipated Phase 1 clinical trial design and timelines for data.